核新生物医药

Hexin Biopharmaceutical is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of next-generation radiopharmaceuticals. The company focuses on the Radionuclide Drug Conjugate (RDC) field, utilizing a theranostic approach to integrate diagnosis and treatment for oncology. Its proprietary platform enables the conjugation of various radionuclides with high-affinity targeting ligands such as small molecules and peptides. Hexin's lead programs, HX01 and HX02, target PSMA and FAP respectively, aiming to address unmet medical needs in prostate cancer and advanced solid tumors. The company is backed by prominent investors including Legend Capital and 6 Dimensions Capital.